Evidence map›Paper›PMID 36549871›Full record

ArticleLife science alliance2023

Unconventional interactions of the TRPV4 ion channel with beta-adrenergic receptor ligands.

Miguel Benítez-Angeles, Emmanuel Juárez-González, Ariela Vergara-Jaque, Itzel Llorente, Gisela Rangel-Yescas, Stéphanie C Thébault, Marcia Hiriart, León D Islas, Tamara Rosenbaum

Open access · goldAbstract read
In one paragraph

Article in Life science alliance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Miguel Benítez-AngelesDepartamento de Neurociencia Cognitiva, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México (UNAM), México, México.
Emmanuel Juárez-GonzálezDepartamento de Neurociencia Cognitiva, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México (UNAM), México, México.
Ariela Vergara-JaqueCenter for Bioinformatics, Simulation and Modeling, Faculty of Engineering, Universidad de Talca, Talca, Chile.
Itzel LlorenteDepartamento de Neurociencia Cognitiva, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México (UNAM), México, México.
Gisela Rangel-YescasDepartamento de Fisiología, Facultad de Medicina, UNAM, México, México.ORCID 0000-0003-2766-6040
Stéphanie C ThébaultInstituto de Neurobiología, UNAM, Campus UNAM-Juriquilla, Querétaro, México.
Marcia HiriartDepartamento de Neurociencia Cognitiva, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México (UNAM), México, México.
León D IslasDepartamento de Fisiología, Facultad de Medicina, UNAM, México, México.
Tamara RosenbaumDepartamento de Neurociencia Cognitiva, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México (UNAM), México, México trosenba@ifc.unam.mx.ORCID 0000-0002-4791-3195
Universidad Nacional Autónoma de México · MXUniversity of Talca · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transient receptor potential vanilloid 4 (TRPV4) ion channel is present in different tissues including those of the airways. This channel is activated in response to stimuli such as changes in temperature, hypoosmotic conditions, mechanical stress, and chemicals from plants, lipids, and others. TRPV4's overactivity and/or dysfunction has been associated with several diseases, such as skeletal dysplasias, neuromuscular disorders, and lung pathologies such as asthma and cardiogenic lung edema and COVID-19-related respiratory malfunction. TRPV4 antagonists and blockers have been described; nonetheless, the mechanisms involved in achieving inhibition of the channel remain scarce, and the search for safe use of these molecules in humans continues. Here, we show that the widely used bronchodilator salbutamol and other ligands of β-adrenergic receptors inhibit TRPV4's activation. We also demonstrate that inhibition of TRPV4 by salbutamol is achieved through interaction with two residues located in the outer region of the pore and that salbutamol leads to channel closing, consistent with an allosteric mechanism. Our study provides molecular insights into the mechanisms that regulate the activity of this physiopathologically important ion channel.

Indexed as

COVID-19Transient Receptor Potential ChannelsAlbuterolHumansLigandsReceptors, Adrenergic, betaTRPV Cation ChannelsAlbuterolLigandsReceptors, Adrenergic, betaTransient Receptor Potential ChannelsTRPV4 protein, humanTRPV Cation Channels

Identifiers

PMID36549871
PMCPMC9780703
OpenAlexW4312091639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.